BioTuesdays

Author - Leonard Zehr

Capricor Therapeutics Logo
Markets

HCW analyst assumes coverage of Capricor

H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $13 price target. The stock closed at $4.27 on Tuesday. Capricor has developed three...

July 6, 2016
Feature

Merus Labs moving up the value chain

By Len Zehr After an 18-month company transformation under new CEO, Barry Fishman, Merus Labs International (NASDAQ:MSLI; TSX:MSL) is now ready to in-license new pharmaceutical products, in addition to optimizing...

July 5, 2016
Can-Fite Logo
Developments

Can-Fite unit fails Phase 2 glaucoma trial

Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma. No statistically significant differences...

July 5, 2016
Executive Moves

Merus Labs appoints two senior executives

Merus Labs International (NASDAQ:MSLI; TSX:MSL) has appointed two key additions to its executive leadership team, effective July 1.Dr. Michael Bumby was named CFO, succeeding Andrew Patient, who has decided to leave the...

July 5, 2016
Executive Moves

Joint Corp. names Peter Holt as acting CEO

The employment of John Richards as CEO of the Joint Corp. (NASDAQ:JYNT) has been terminated by mutual agreement, effective June 30.  Mr. Richards also resigned as a director. Peter Holt, who was previously COO, was...

July 5, 2016
CymaBay Therapeutics
Markets

Roth resumes coverage of CymaBay

Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday. “In our opinion, while catalysts for the next 12-to-18...

July 5, 2016
Galectin Therapeutics
Markets

Roth resumes coverage of Galectin Therapeutics

Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD...

July 5, 2016